-
-
-
-
-
-
-
Voyxact 24-month data shows kidney function improvement in IgAN, BTIG comments
-
-
-
-
-
-
-
Climb Bio, Inc. (CLYM) Tops Q1 EPS by 9c
-
-
-
-
-
-
-
Truist Securities Starts Climb Bio (CLYM) at Buy
-
-
-
-
-
-
-
Freedom Capital Markets Starts Climb Bio (CLYM) at Buy
-
-
-
-
-
-
-
Climb Bio reports preclinical data for IgAN drug candidate
-
-
-
-
-
-
-
Climb Bio (CLYM) Appoints Kim Cobleigh Drapkin and Bo Cumbo to its Board
-
-
-
-
-
-
-
Eliem Therapeutics (ELYM) Rebrands as Climb Bio (CLYM)
460,607 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

